MedTrace Logo

Healaflow Patch for the Treatment of Rhegmatogenous Retinal Detachment

NCT03542162 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2019-04-30

No results posted yet for this study

Summary

To report the surgical results of primary rhegmatogenous retinal detachment (RRD) repaired by 27G pars plana vitrectomy (PPV) combined with Healaflow patch and air tamponade, and do not need prone position postoperation.

Conditions

  • Rhegmatogenous Retinal Detachment

Interventions

BIOLOGICAL

Healaflow

For the RRD patients, after 27G PPV, air-liquid exchange and endolaser photocoagulation around the tear(s), Healaflow is going to be fully covered on the surface of all retinal tears using 27G needle, the amount of Healaflow injection was determined according to the size of tears.

Sponsors & Collaborators

  • Tianjin Medical University Eye Hospital

    lead OTHER

Principal Investigators

  • Xiaorong Li, MD, PhD · Tianjin Medical University Eye Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2018-07-01
Completion
2018-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542162 on ClinicalTrials.gov